Androisoxazole

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Androisoxazole
Androisoxazole.png
Clinical data
Trade names Neo-Ponden, Neo-Pondus
Routes of
administration
Oral
Identifiers
Synonyms 17α-Methyl-5α-androstano[3,2-c]isoxazol-17β-ol
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C21H31NO2
Molar mass 329.476 g/mol
3D model (Jmol)
  (verify)

Androisoxazole (brand names Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy.[1][2][3][4] It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring,[4] and is also related to furazabol, prostanozol, and danazol.

References[edit]

  1. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1. 
  2. ^ Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 384–. ISBN 978-3-642-66353-6. 
  3. ^ ANTONINI FM, VERDI G (October 1961). "[Preliminary results of experience with a new anabolic steroid, "androisoxazole," in the aged.]". Minerva Medica (in Italian). 52: 3437–41. PMID 13861810. 
  4. ^ a b ARNOLD A, POTTS GO, BEYLER AL (December 1963). "RELATIVE ORAL ANABOLIC TO ANDROGENIC ACTIVITY RATIOS OF ANDROISOXAZOLE, ETHYLESTRENOL, METHYLANDROSTENOLISOXAZOLE AND TESTOSTERONE". Acta Endocrinologica. 44: 490–8. PMID 14082537.